OliFuco ®

Oligo Fucoidan
(Low Molecular Weight Fucoidan)

Health Ingredient Verified with Human Clinical Trial

Bi-directional Immunomodulatory Activity

Fucoidan is a kind of polysaccharide containing sulfated fucose, which is extracted from seaweeds and can be utilized as dietary supplement, health functional food or beverage products. Hi-Q acquired unique extraction technology from government agency institute and improved the technology by it's own efforts to produce 500-1500 Daltons low molecular weight Fucoidan. We further focus on scientific researches and human clinical trials to proven safety & functional efficacy; thus with 25+ scientific & medical publication journals accepted by international professional authoritative to prove our scientific data & health claims, and evidences of efficacy scientifically.

Product features

Botanical Origin	Laminaria Japonica
Molecular Size	500-1500 Daltons
Heavy Metal (As)	≤1ppm
Heavy Metal (Pb)	≤1.5ppm
Water-Soluble Polysaccharides	≥65%
Packaging	2 kg/pack; 20kg/Carton
Safety & Quality Testing	Every lot of production
Shelf Life	3 years

Appearance	Light brown powder
Flavor	No odor; Slight seaweed taste
Heat & Stability	100 °C (1 hour) ; 121 °C (30 mins)
Suggest Use & Suitable for	Immune Modulation : 0.5 -1.5 g/day
Adjuvant Functional Support for Medical Purpose	4 -6 g/day

* Consult with professional dietitian or physician

Application

Product form as capsules, tablets, Solid drinks, powder sachets. Suitable for all kinds of health supplement, functional food & nutritional formulation products

OliFuco ® Oligo Fucoidan Research & Support Evidences

More than 25 peer-reviewed research papers have been published on the bioactive properties of our ingredients, including comprehensive in vitro investigations, animal studies and human clinical trials.



Improved Disease-Control Rate up to 92.8% (Metastatic colorectal cancer patients)

A Double-Blind Randomized, placebo-controlled Clinical Trial Kaohsiung Medical University Hospital



Table 2 The comparison of responders and disease-control rate between the Fucoidan group and the Non-Fucoidan group via Chi-Square test

	Total	Fucoidan	Non-Fucoidan	
	(N = 54)	(N = 28)	(N = 26)	*P*-value
	N	N (%)	N (%)	
Responder				0.284
Yes (CR+PR)*	29	17 (60.7)	12 (46.2)	
No (SD+PD)*	25	11 (39.3)	14 (53.8)	
Disease-control rate				0.026
Yes (CR+PR+SD)*	44	26 (92.8)	18 (69.2)	
No (PD)*	10	2 (7.2)	8 (30.8)	

*CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease and classified by RECIST criteria Version 1.1



Primary Endpoints

- The DCR, defined as the sum of the CR, PR, and SD rates, was significantly higher (by 23.6%) in the study group than in the control group (92.8% vs. 69.2%; p = 0.026).

Secondary Endpoints

- Secondary Outcome CR and PR rates was comparable in the study group and the control group (60.7% vs. 46.2% ; p=0.284). Compared with the control group, the study group exhibited a trend of improved OS (18.04±0.91 vs. 12.96±0.83 months ; p=0.092).

No Adverse Effects were observed in both groups during the trial period.

† Tsai, H., Tai, C., Huang, C., Chang, F. and Wang, J. (2017). Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Marine Drugs, 15(12), p.122. ALL INFORMATION CONTAINED IN THIS BROUCHER IS PROVIDED FOR SCIENTIFIC RESEARCH & PRODUCT DEVELOPMENT PURPOSES. HIGHLIGHTS OF SCIENTIFIC DATA, FIGURE & TABLE INFORMATION ARE PROVEN BY THE RESEARCH STUDIES